

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4152-1-PUS-7	SERIAL NO. Not Yet Assigned
	APPLICANT COX	
	FILING DATE February 5, 2004	GROUP ART

U.S. PATENT DOCUMENTS


*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
1D	1	4,588,585	5/13/86	Mark et al.	424	85	
1D	2	5,166,322	11/24/92	Shaw et al.	530	351	
1D	3	5,206,344	4/27/93	Katre et al.	530	351	
1D	4	5,208,158	5/4/93	Bech et al.	435	219	
1D	5	5,766,897	6/16/98	Braxton	435	172.1	
1D	6	5,849,535	12/1998	Cunningham et al.	435	243	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
1D	7	0 458 064 A2	11/1991	Europe				
1D	8	WO 93/00109	7/1993	PCT				
1D	9	WO 95/11987	4/1995	PCT				
1D	10	WO 96/31537	10/1996	PCT				
1D	11	WO 95/32003	11/1995	PCT				


OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

	12	Bazan, <i>Immunology Today</i> , 11:350-354 (1990)
1D	13	Campbell et al., <i>J. Peptide Res.</i> , 49:527-537 (1997)
1D	14	Cunningham et al., <i>Science</i> , 243:1330-1336 (1989)
1D	15	Goodson and Katre, <i>Bio/Technology</i> , 8:343-346 (1990)
1D	16	Karpusas et al., <i>Proc. Natl. Acad. Sci. USA</i> , 94:11813-11818 (1997)
1D	17	Lowman and Wells, <i>J. Mol. Biol.</i> , 234:564-578 (1993)


EXAMINER 	DATE CONSIDERED 09/27/2006
*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4152-1-PUS-7	SERIAL NO. Not Yet Assigned
	APPLICANT COX	
	FILING DATE February 5, 2004	GROUP ART

10	18	Mott and Compbell, <i>Curr Opin Struct Biol</i> , 5:114-121 (1995)
10	19	Sprang and Bazan, <i>Curr. Op. Struct. Biol.</i> , 3:815-827 (1993)
10	20	Wells, <i>Ann. Rev. Biochem.</i> , 65:609-634 (1996).
10	21	Zalipsky, S., <i>Adv. Drug Delivery Rev.</i> , 16:157-182 (1995)

EXAMINER 	DATE CONSIDERED 09/27/2006
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	09/27/2006
-----------------------	---	--------------------	------------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/773,939
Filing Date	February 5, 2004
First Named Inventor	Cox
Art Unit	1647
Examiner Name	Dang, Ian D.
Attorney Docket Number	4152-1-PUS-7

Sheet


2

of

3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
1D	6	Paul et al., Proceedings of the National Academy of Sciences, USA, Volume 87, No. 19, pp. 7512-7516 (Oct 1990)	
1D	7	Kawashima et al. FEBS Letters, Volume 283 No. 2, pp. 199-202 (June 1991)	
1D	8	Bowie et al., Science, Vol 247 No. 4948, pp. 1306-1310 (March 1990)	
1D	9	Barton et al., The Journal of Biological Chemistry, Vo. 274 No. 9, pp. 5755-5761 (February 1999)	
1D	10	Tacken et al., European Journal of Biological Chemistry, Vo. 265 No. 2, pp. 645-655 (October 1999)	
1D	11	Czupryn et al., Journal of Biological Chemistry, Vol. 270 No. 2, pp. 978-985 (January 1995)	
1D	12	Czupryn et al., Annals of the New York Academy of Sciences, Vol. 762, pp. 152-164 (July 1995)	
1D	13	Miyadi et al., Bioscience, Biotechnology and Biochemistry, Vol. 60 No. 3, pp. 541-542 (March 1996)	
1D	14	Wells, Biochemistry, Vol. 29 No. 37, pp. 8509-17 (September 1990)	
1D	15	Zhang et al., Pharmaceutical Research, Vol. 19 No. 8, pp. 1223-1231 (August 2002)	

Examiner
SignatureDate
Considered

09/26/2006

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/773,939		
		Filing Date	February 5, 2004		
		First Named Inventor	Cox		
		Art Unit	1647		
		Examiner Name	Dang, Ian D.		
Sheet	3	of	3	Attorney Docket Number	4152-1-PUS-7

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LD	16	Yamasaki et al., Drugs Under Experimental and Clinical Research, Vol. 24 No. 4, pp. 191-196 (1998)	

Examiner Signature		Date Considered	09/27/2006
--------------------	---	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.